HHS lets compounders make six unapproved peptides despite FDA objections

· Health · United States

The Trump administration is giving the peptide craze a regulatory boost by allowing compounding pharmacies to make six unapproved peptides, despite objections from FDA career scientists. The peptides had controversially won a contested recommendation from outside advisers to the FDA in July. HHS Secretary Robert F. Kennedy Jr. has signaled the agency won't take enforcement action on the six products. The move drew pushback, including from Michigan Democratic Senate candidate Abdul El-Sayed, who challenged Kennedy's claims, and it follows earlier steps easing enforcement on certain wellness peptides. For the compounding and peptide sectors, the policy widens the space between what regulators approve and what pharmacies may legally produce, a boundary that has been shifting under the current HHS leadership.

Why it matters：Loosening enforcement on unapproved peptides tests how far regulators can diverge from their own scientists, with implications for compounding pharmacies and supplement-adjacent drug markets.

Key points

  • Six unapproved peptides are covered by the policy.
  • FDA career scientists objected to the move.
  • The peptides had won a contested outside-adviser recommendation in July.

Sources (original reporting)

More stories from this day